Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer.
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cancer Vaccines
/ administration & dosage
Drug Resistance, Neoplasm
Female
Humans
Immunization Schedule
Middle Aged
Peptides
/ administration & dosage
Treatment Outcome
Triple Negative Breast Neoplasms
/ immunology
Vaccines, Subunit
/ administration & dosage
advanced metastatic triple-negative breast cancer
early phase II trial
immunotherapy
mixed-peptide vaccine
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
10
04
2020
revised:
26
05
2020
accepted:
28
05
2020
pubmed:
5
6
2020
medline:
15
12
2020
entrez:
5
6
2020
Statut:
ppublish
Résumé
We undertook an early phase II study of mixed 19-peptide cancer vaccine monotherapy for 14 advanced metastatic triple-negative breast cancer (mTNBC) patients refractory to systemic chemotherapy to develop a new type of cancer vaccine. The treatment protocol consisted of a weekly vaccination for 6 weeks, and there were no severe adverse events related to the vaccination throughout the trial. Increase of peptide-specific IgG against the vaccinated human leukocyte antigen-matched peptides, but not against the nonmatched peptides, was positively correlated with overall survival (OS) (P < .01). The median OS was 11.5 or 24.4 months in all 14 patients or the 10 patients who completed the vaccination. The patients with lower C-reactive protein levels or 3 or fewer systemic chemotherapies were favorable candidates for this treatment. Advancement of this therapy to the next stage of study could be warranted based on the safety and immune boosting determined herein (clinical trial registration number: UMIN000014616).
Identifiants
pubmed: 32495455
doi: 10.1111/cas.14510
pmc: PMC7419019
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Peptides
0
Vaccines, Subunit
0
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2760-2769Subventions
Organisme : The Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 26461965
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Neuro Oncol. 2019 Feb 19;21(3):348-359
pubmed: 30500939
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cancer Immunol Immunother. 2015 Apr;64(4):493-505
pubmed: 25662406
Cancer Sci. 2018 Mar;109(3):611-617
pubmed: 29388341
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Cancer Sci. 2017 Jan;108(1):81-90
pubmed: 27801993
Int J Oncol. 2015 Jan;46(1):55-62
pubmed: 25310280
Genes Chromosomes Cancer. 2012 Sep;51(9):832-40
pubmed: 22585709
Curr Med Chem. 2014;21(21):2332-45
pubmed: 24524766
Breast. 2018 Jun;39:131-138
pubmed: 29679849
Cancer Immunol Res. 2014 Dec;2(12):1154-62
pubmed: 25351849
Br J Cancer. 2010 Sep 7;103(6):899-909
pubmed: 20717116
Cancer Sci. 2015 Sep;106(9):1111-7
pubmed: 26122553
J Immunother. 2005 Nov-Dec;28(6):535-41
pubmed: 16224270
Oncoimmunology. 2018 Sep 6;7(12):e1511506
pubmed: 30524907
Eur J Cancer. 2018 Jun;96:17-24
pubmed: 29660596
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Cancer Sci. 2016 May;107(5):590-600
pubmed: 26920496
Nat Commun. 2013;4:2617
pubmed: 24135919
N Engl J Med. 2011 Jun 2;364(22):2119-27
pubmed: 21631324
Breast Cancer Res. 2014 Jul 03;16(4):R70
pubmed: 24992895
Evid Based Complement Alternat Med. 2016;2016:5929525
pubmed: 27703488
Folia Histochem Cytobiol. 2006;44(3):165-72
pubmed: 16977795
Cancer Sci. 2020 Aug;111(8):2760-2769
pubmed: 32495455
Clin Cancer Res. 2004 Feb 1;10(3):929-37
pubmed: 14871969